Oppenheimer Asset Management Inc. Has $404,000 Stock Position in Smith & Nephew plc (NYSE:SNN)

Oppenheimer Asset Management Inc. increased its holdings in Smith & Nephew plc (NYSE:SNN) by 41.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,298 shares of the medical equipment provider’s stock after acquiring an additional 4,743 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Smith & Nephew were worth $404,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Equity Investment Corp raised its stake in shares of Smith & Nephew by 27.3% in the second quarter. Equity Investment Corp now owns 14,921 shares of the medical equipment provider’s stock worth $370,000 after purchasing an additional 3,200 shares during the last quarter. American Century Companies Inc. grew its holdings in Smith & Nephew by 9.3% during the second quarter. American Century Companies Inc. now owns 119,347 shares of the medical equipment provider’s stock worth $2,957,000 after buying an additional 10,156 shares in the last quarter. Rhumbline Advisers lifted its stake in Smith & Nephew by 8.6% during the 2nd quarter. Rhumbline Advisers now owns 10,365 shares of the medical equipment provider’s stock valued at $257,000 after acquiring an additional 819 shares in the last quarter. Natixis Advisors LLC boosted its holdings in Smith & Nephew by 12.0% during the 2nd quarter. Natixis Advisors LLC now owns 78,668 shares of the medical equipment provider’s stock worth $1,949,000 after acquiring an additional 8,420 shares during the last quarter. Finally, Hantz Financial Services Inc. purchased a new position in Smith & Nephew during the 2nd quarter worth $1,549,000. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 5th. UBS Group raised Smith & Nephew from a “neutral” rating to a “buy” rating in a research report on Wednesday, June 5th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Smith & Nephew in a research report on Wednesday, July 24th. They set a “buy” rating for the company. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Smith & Nephew presently has a consensus rating of “Moderate Buy”.

Smith & Nephew Trading Down 1.2 %

Smith & Nephew stock opened at $30.57 on Friday. The business’s 50 day simple moving average is $30.09 and its 200 day simple moving average is $27.09. Smith & Nephew plc has a 12 month low of $21.52 and a 12 month high of $31.72. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63.

Smith & Nephew Increases Dividend

The company also recently declared a dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 4th will be paid a dividend of $0.288 per share. This is an increase from Smith & Nephew’s previous dividend of $0.24. The ex-dividend date is Friday, October 4th.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.